Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock code: 002940) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6, 2025, and June 9, 2025) [1] - The company's board of directors conducted an investigation into the abnormal trading situation and confirmed that there were no undisclosed significant information or major changes affecting the company [1][2] - The only ongoing project is ALK-N001, which received clinical trial approval in April 2025 and is currently in Phase I clinical trials, highlighting the long cycle, high investment, and uncertainty associated with innovative drug development [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, nor any significant information that could impact the stock price [2] - The company emphasizes the importance of rational decision-making for investors, given the inherent risks in the long and costly drug development process [2]

浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002940 证券简称：昂利康 公告编号：2025-043 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 2 个交易日（2025 年 6 月 6 日、2025 年 6 月 9 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规 则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如下： 1、公司前期披露的信息不存在需要更正或补充披露的事项； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、经核查，公司目前经营情况正常，主营业务未发生变化，内外部经营环 境未发生重大变化； 4、经核查，公司及控股股东、实际控制人不存在关于本公司的应披露而未 披露的重大事项，也不存在处于筹划阶段的重大事项； 一、股票交易异常波动的情况介绍 三、是 ...

Core Viewpoint - The company, Angli Kang (002940.SZ), has experienced significant stock price fluctuations, with a cumulative deviation of over 20% in closing prices over two consecutive trading days, attributed to abnormal trading activity [1] Company Summary - The company confirmed that there are no corrections or supplementary disclosures needed for previously released information, and there have been no significant changes in the internal or external operating environment [1] - The company and its controlling shareholders have not engaged in any stock trading during the period of abnormal price fluctuations [1] - The innovative drug project ALK-N001 is currently in Phase I clinical trials, characterized by a long research and development cycle and substantial investment requirements, indicating potential investment risks for investors [1]

Core Viewpoint - The company, Anglikang (002940), has experienced a significant stock price fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days, indicating abnormal trading activity [1] Company Summary - The only innovative drug project currently under research by the company is ALK-N001, which received approval for clinical trial notification in April 2025 [1] - As of the date of this announcement, ALK-N001 is still in the Phase I clinical trial stage [1] Industry Summary - The research and development of innovative drugs are characterized by long cycles, high investment, and significant uncertainty [1]

Group 1 - The A-share market's innovative drug concept stocks have shown strong performance, with the innovative drug sector index reaching a historical high [1] - Notable individual stock performances include Xinghao Pharmaceutical rising over 25%, RuiZhi Pharmaceutical hitting a 20% limit up, and Changshan Pharmaceutical reaching a historical high [1][2] - The overall pharmaceutical sector has experienced a prolonged adjustment period, resulting in low valuations and underweight public holdings, indicating potential for recovery and structural opportunities [2] Group 2 - Specific stock performances include: - Xinghao Pharmaceutical: 25.82% increase, market cap of 3.045 billion [2] - RuiZhi Pharmaceutical: 19.98% increase, market cap of 5.801 billion [2] - Changshan Pharmaceutical: 19.97% increase, market cap of 47.9 billion [2] - Shutaishen: 12.12% increase, market cap of 15.6 billion [2] - The report from China Galaxy Securities suggests that the pharmaceutical market is expected to see continuous recovery and that innovative drug companies will benefit from policy support and improved payment conditions by 2025 [2]

Pharmaceutical Industry - Several companies in the innovative drug sector have shown significant stock price increases, with notable performances including Ruizhi Pharmaceutical up by 19.98% and Longxin Pharmaceutical up by 10.04% [2][3] - The overall sentiment in the innovative drug investment environment is improving, with a resurgence in financing activities for sectors like peptides and ADCs, which is expected to boost the CXO industry [11] Solid-State Battery - Solid-state batteries are projected to begin vehicle testing by 2027 and achieve mass production by 2030, leading to stock price increases for companies like Dexin Technology, which rose by 10.01% [4] - Other companies involved in solid-state battery technology, such as Hailan Pharmaceutical and Yinglian Co., also experienced significant stock gains [6] Digital Currency - The listing of Circle, the first stablecoin company, saw a 29.4% increase in stock price, influencing related stocks like Jinshi Technology, which rose by 9.97% [7] Robotics - The upcoming World Humanoid Robot Games is expected to showcase advancements in robotics, positively impacting stocks like Dongbei Group, which increased by 9.99% [8][10] Agriculture and Pesticides - ST Hongyang announced a price increase for its chlorantraniliprole product to 300,000 yuan per ton, a significant rise from last year's low of 210,000 yuan, benefiting companies like Lianhua Technology [13][14] Rare Earth Permanent Magnet - The Chinese government has implemented export controls on rare earths, which aligns with international practices, leading to stock price increases for companies like Beikong Technology [15][16] Sports Industry - The Hong Kong Legislative Council is set to discuss regulations for basketball betting, which may positively affect stocks in the sports sector, such as Gongchuang Turf [19] Military Industry - Indonesia's consideration of China's J-10 fighter jet, based on its performance in conflicts, is influencing military-related stocks like Lijun Co. [20] Financial Sector - Recent approvals for changes in actual controllers of several securities firms, including Changcheng Guorui Securities, have led to stock price increases in the financial sector [22] Food and Beverage - Morgan Stanley's report indicates improving sentiment among international investors towards Chinese stocks, particularly in the "new consumption" and technology sectors, benefiting companies like XD Jiao Da Ang [23] Dental Medical - A forecast by Frost & Sullivan predicts a significant increase in the demand for dental implants in China, with a compound annual growth rate of 30.97%, positively impacting stocks like Haochen Medical [26][27] Automotive Industry - China's electric vehicle exports have grown by 19% in the first five months of the year, leading to stock price increases for companies like Jianghuai Automobile [30][32]

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

创新药板块局部活跃，海辰药业（300584）涨超10%，联化科技（002250）涨超8%，圣诺生物、迈威 生物、昂利康（002940）等股拉升。 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-042 浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到<贷款承诺书>的公告》（公告编号： ...

证券代码：002940 证券简称：昂利康 公告编号：2025-041 浙江昂利康制药股份有限公司 关于使用 2020 年非公开发行股票闲置募集资金 暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"本公司"或"公司"或"昂利康"） 于 2025 年 5 月 16 日召开第四届董事会第九次会议和第四届监事会第七次会议， 审议通过了《关于使用 2020 年非公开发行股票闲置募集资金暂时补充流动资金 的议案》，同意公司使用不超过 5,000 万元的 2020 年非公开发行股票闲置募集资 金暂时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月，该议 案无需提交股东大会审议，到期归还募集资金专用账户。现将具体情况公告如下： 一、2020 年非公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准浙江昂利康制药股份有限公司非公开 （证监许可〔2020〕2271 号）核准，并经深圳证券交易所同意， 发行股票的批复》 本公司由主承销商东方证券股份有限公司（以下简称"东方证券"或"保荐机构"） ...